EkhartYoga joins YogaEasy family
25.5.2023 08:00:00 CEST | news aktuell GmbH | Press release
The leading online yoga platforms in Germany and the Netherlands announce that they are joining forces.
Hamburg/Amsterdam, 25 May, 2023: YogaEasy and EkhartYoga are uniting their expertise and resources to maximise access to high-quality online yoga. Their offerings will expand to more than 5,000 yoga and meditation videos in German and English, with more than 80 teachers. In addition, customers will benefit from a greater range of functions to make it even easier for them to practice. This European alliance promises great growth potential with a bilingual app offering English and German content in the planning.
Founded in 2010, Hamburg-based YogaEasy was Germany’s first online yoga studio and counts authorities such as Anna Trökes, Dr. Ronald Steiner and Nicole Bongartz among its teaching team. EkhartYoga was set up in Amsterdam in 2008 by Esther Ekhart and is known across Europe for its high-quality videos exclusively in English, with expert teachers including David Lurey, Tashi Dawa and Katy Appleton. The classes from both partners are professionally produced by yogis for yogis. They offer a huge variety of styles whilst honouring the lineage and philosophy of yoga.
YogaEasy founder Dr. Henrike Fröchling: “We have decided to join forces with EkhartYoga, as we share a single mindset, for example regarding the content quality and our esteem for our teachers. I’m looking forward to expanding into the English-speaking market and to working on our vision: Creating the best online yoga experience.”
EkhartYoga founder Esther Ekhart adds: “I’m delighted to work with YogaEasy, together we can bring the beautiful and transformational practice of yoga to even more people. Our family is growing and I'm excited about what we'll be able to bring to the yoga world!”
The Process was supported by Quantum Partners in Munich.
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
Grünenthal successfully completes Phase I trial with Nociceptin Receptor (NOP) Agonist29.6.2026 12:28:23 CEST | Press release
The investigational compound has a unique mechanism of action and the potential to become a first-in-class therapy option for the treatment of acute and chronic pain. In a Phase I trial, the investigational compound was demonstrated to be safe and well tolerated. A Phase II trial will commence later this year.
FRITZ: YouGov survey in 14 countries: Trust in router manufacturers from different regions European consumers mistrust Chinese routers29.6.2026 10:00:00 CEST | Press release
More than half of consumers in Norway mistrust routers from Chinese manufacturers (59%) Many mistrust devices made in the USA European routers enjoy a high level of trust across Europe (60%) For half of Europeans (55%), the ‘Made in Europe’ label important to when making a purchase
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom